癌症免疫疗法的最新进展。
Recent Advances in Cancer Immunotherapy.
机构信息
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan.
出版信息
Biomolecules. 2021 Feb 23;11(2):335. doi: 10.3390/biom11020335.
Abstract
The strategy to use the immune system to fight cancer is not a novel concept; in 1891, Coley reported the treatment of three cases of sarcoma by inoculation with erysipelas [...].
摘要
利用免疫系统对抗癌症的策略并不是一个新概念；早在 1891 年，科利就报道了用丹毒菌接种治疗三例肉瘤的情况[...]。
相似文献
1
Recent Advances in Cancer Immunotherapy.癌症免疫疗法的最新进展。
Biomolecules. 2021 Feb 23;11(2):335. doi: 10.3390/biom11020335.
2
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5-7, 2017.意大利肿瘤生物治疗网络（NIBIT）关于癌症生物免疫治疗的第十五次会议，意大利锡耶纳，2017年10月5日至7日。
Cancer Immunol Immunother. 2019 Jan;68(1):151-158. doi: 10.1007/s00262-018-2222-0. Epub 2018 Aug 9.
3
Immuno-oncology-101: overview of major concepts and translational perspectives.免疫肿瘤学 101：主要概念和转化视角概述。
Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8.
4
"Tumor immunology meets oncology (TIMO) XV", April 25th-27th 2019, Halle/Saale, Germany.“肿瘤免疫学与肿瘤学（TIMO）XV”会议将于 2019 年 4 月 25 日-27 日在德国哈勒/萨勒召开。
Cancer Immunol Immunother. 2020 May;69(5):901-909. doi: 10.1007/s00262-020-02491-1. Epub 2020 Feb 5.
5
Models for Immuno-oncology Research.免疫肿瘤学研究模型。
Cancer Cell. 2020 Aug 10;38(2):145-147. doi: 10.1016/j.ccell.2020.07.010.
6
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.2014年癌症免疫治疗进展：癌症免疫治疗协会第12届年会报告——2014年5月6 - 8日于德国美因茨召开
Hum Vaccin Immunother. 2014;10(10):3090-100. doi: 10.4161/hv.29767.
7
[Which future for B lymphocytes infiltrating solid tumors: prognostic biomarker and/or therapeutic target?].浸润实体瘤的B淋巴细胞的未来走向如何：预后生物标志物及/或治疗靶点？
Med Sci (Paris). 2018 Jan;34(1):72-78. doi: 10.1051/medsci/20183401016. Epub 2018 Jan 31.
8
"Tumor immunology meets oncology (TIMO) XII", April 28th-30th 2016, Halle/Saale, Germany.2016年4月28日至30日于德国哈雷/萨勒举办的“肿瘤免疫学与肿瘤学交汇（TIMO）第十二届会议”
Cancer Immunol Immunother. 2017 Nov;66(11):1497-1503. doi: 10.1007/s00262-017-2037-4. Epub 2017 Jul 10.
9
Principles of immunotherapy.免疫疗法的原则。
J Natl Compr Canc Netw. 2015 May;13(5 Suppl):670-2. doi: 10.6004/jnccn.2015.0199.
10
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.SITC 2018 研讨会报告：免疫肿瘤生物标志物：最新进展。
J Immunother Cancer. 2018 Dec 4;6(1):138. doi: 10.1186/s40425-018-0453-4.
引用本文的文献
1
Racial and socioeconomic disparities in survival improvement of eight cancers.八种癌症生存改善方面的种族和社会经济差异。
BJC Rep. 2024 Mar 11;2(1):21. doi: 10.1038/s44276-024-00044-y.
2
The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.用于预测膀胱尿路上皮癌预后和免疫治疗反应的G蛋白偶联受体相关基因特征。
Open Life Sci. 2023 Aug 10;18(1):20220682. doi: 10.1515/biol-2022-0682. eCollection 2023.
3
Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy.靶向纳米药物重塑免疫抑制性肿瘤微环境以增强癌症免疫治疗。
Acta Pharm Sin B. 2022 Dec;12(12):4327-4347. doi: 10.1016/j.apsb.2022.11.001. Epub 2022 Nov 4.
本文引用的文献
1
A decade of immune-checkpoint inhibitors in cancer therapy.免疫检查点抑制剂在癌症治疗中的十年。
Nat Commun. 2020 Jul 30;11(1):3801. doi: 10.1038/s41467-020-17670-y.
2
The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.免疫疗法在与癌症相关的原发性免疫缺陷儿童中的应用可能性。
Biomolecules. 2020 Jul 28;10(8):1112. doi: 10.3390/biom10081112.
3
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.免疫检查点抑制剂耐药的表观遗传机制。
Biomolecules. 2020 Jul 16;10(7):1061. doi: 10.3390/biom10071061.
4
Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.免疫抑制细胞作为黑色素瘤和非黑色素瘤皮肤癌免疫治疗靶点的意义。
Biomolecules. 2020 Jul 22;10(8):1087. doi: 10.3390/biom10081087.
5
Vitamin D Prevents Pancreatic Cancer-Induced Apoptosis Signaling of Inflammatory Cells.维生素 D 可阻止炎性细胞的胰腺癌诱导凋亡信号。
Biomolecules. 2020 Jul 15;10(7):1055. doi: 10.3390/biom10071055.
6
The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors.实体瘤中检查点抑制剂的耐药机制。
Biomolecules. 2020 Apr 25;10(5):666. doi: 10.3390/biom10050666.
7
Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas.纯实性与部分实性肺腺癌中 PD-L1 表达状态的比较。
Biomolecules. 2019 Sep 7;9(9):456. doi: 10.3390/biom9090456.
8
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).表达程序性细胞死亡配体1（PD-L1）的肺癌的临床和病理特征
Lung Cancer. 2016 Aug;98:69-75. doi: 10.1016/j.lungcan.2016.04.021. Epub 2016 May 25.
9
II. Contribution to the Knowledge of Sarcoma.二、对肉瘤知识的贡献
Ann Surg. 1891 Sep;14(3):199-220. doi: 10.1097/00000658-189112000-00015.
Zotero 插件